A global analysis of Telavancin activity against Gram-Positive Pathogens isolated from the bone/joint infections across different regions : SENTRY Program collection

Trial Profile

A global analysis of Telavancin activity against Gram-Positive Pathogens isolated from the bone/joint infections across different regions : SENTRY Program collection

Completed
Phase of Trial: Phase III/IV

Latest Information Update: 20 Jun 2016

At a glance

  • Drugs Telavancin (Primary)
  • Indications Gram-positive infections; Osteomyelitis
  • Focus Therapeutic Use
  • Most Recent Events

    No Data Available
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top